Golimumab treatment elicited significantly better responses than placebo in week 14 ASAS20 response [ 49.1 % ( 53/108 ) vs 24.8 % ( 26/105 ) , respectively , P < 0.001 ] , week 24 ASAS20 response ( 50.0 % vs 22.9 % , P < 0.001 ) and mean improvements in BASFI ( -1.26 vs 0.11 , P < 0.001 ) and BASMI ( -0.42 vs -0.19 , P = 0.021 ) scores at week 14 .